- Home
- NVA vs BEAT Comparison
NVA vs BEAT Comparison
Compare NVA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVA
- BEAT
- Stock Information
- Founded
- NVA 1987
- BEAT 2015
- Country
- NVA Australia
- BEAT United States
- Employees
- NVA N/A
- BEAT N/A
- Industry
- NVA
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- NVA
- BEAT Technology
- Exchange
- NVA NYSE
- BEAT Nasdaq
- Market Cap
- NVA 62.5M
- BEAT 65.1M
- IPO Year
- NVA N/A
- BEAT 2021
- Fundamental
- Price
- NVA $11.88
- BEAT $2.08
- Analyst Decision
- NVA
- BEAT Buy
- Analyst Count
- NVA 0
- BEAT 1
- Target Price
- NVA N/A
- BEAT $8.00
- AVG Volume (30 Days)
- NVA 31.0K
- BEAT 131.3K
- Earning Date
- NVA 01-01-0001
- BEAT 03-19-2025
- Dividend Yield
- NVA N/A
- BEAT N/A
- EPS Growth
- NVA N/A
- BEAT N/A
- EPS
- NVA N/A
- BEAT N/A
- Revenue
- NVA N/A
- BEAT N/A
- Revenue This Year
- NVA N/A
- BEAT N/A
- Revenue Next Year
- NVA N/A
- BEAT N/A
- P/E Ratio
- NVA N/A
- BEAT N/A
- Revenue Growth
- NVA N/A
- BEAT N/A
- 52 Week Low
- NVA $4.35
- BEAT $1.35
- 52 Week High
- NVA $19.00
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- NVA N/A
- BEAT 39.34
- Support Level
- NVA N/A
- BEAT $2.05
- Resistance Level
- NVA N/A
- BEAT $2.37
- Average True Range (ATR)
- NVA 0.00
- BEAT 0.18
- MACD
- NVA 0.00
- BEAT -0.02
- Stochastic Oscillator
- NVA 0.00
- BEAT 21.24
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.